PGEU GPUE Pharmaceutical Group of European Union Groupement Pharmaceutique de l’Union Européenne...
-
Upload
shonda-daniels -
Category
Documents
-
view
229 -
download
0
Transcript of PGEU GPUE Pharmaceutical Group of European Union Groupement Pharmaceutique de l’Union Européenne...
PGEU GPUE Pharmaceutical Group of European UnionGroupement Pharmaceutique de l’Union Européenne
MHEALTH
PGEU GPUE Pharmaceutical Group of European UnionGroupement Pharmaceutique de l’Union Européenne
AustriaBelgiumBulgariaBosnia
HerzegovinaCyprus
Czech RepDenmarkEstoniaFinlandFrance
GermanyGreece
HungaryIreland
ItalyLuxembourg
MaltaNetherlands
PolandPortugalRomaniaSlovakiaSlovenia
SpainSweden
United KingdomCroatia
FYR MacedoniaNorwaySerbia
SwitzerlandTurkey
Pharmaceutical Group of European UnionMembers: Professional Bodies & Pharmacists’ Associations
2014: 32 Countries
PGEU GPUE Pharmaceutical Group of European UnionGroupement Pharmaceutique de l’Union Européenne
Health Apps IMS study found that just 5 apps account for 15% of market,
and two of these are calorie counters;
Half of healthcare apps have only been downloaded 500 times;
The market is overwhelmingly dominated by lifestyle and wellness apps with very few diagnostic or even adherence apps;
There is no evidence [e.g. RCTs] that apps are effective;
There is an inverse relationship between smartphone use and healthcare need. This may change, but not for a long time.
PGEU GPUE Pharmaceutical Group of European UnionGroupement Pharmaceutique de l’Union Européenne
Remote Monitoring
PGEU GPUE Pharmaceutical Group of European UnionGroupement Pharmaceutique de l’Union Européenne
Remote Monitoring Strong evidence that telemonitoring offers no health
benefits over normal care;
Significant problems remain in the area of data transfer and poor adherence – in the NEJM study nearly half trial participants failed to adhere and 14% dropped out immediately;
Chain of Trust study showed that patients and health professionals considered the telehealth agenda to be manufacturer driven.
PGEU GPUE Pharmaceutical Group of European UnionGroupement Pharmaceutique de l’Union Européenne
The Dilemmas of M Health M Health as a consumer appendage e.g wellness apps is at present a
highly marginal phenonemon in terms of overall health service provision, and likely to remain so for the foressable future;
‘Strong’ M Health (e.g. remote diagnosis and monitoring) needs to break into the mainstream of organised and funded health care. But this is likely to be based on efficiency imperatives, not on patient need, choice or empowerment.
The overall impact of M Health on the technologically incompetent, or averse is unknown, but a case can be made that it will increase health inequalities and undermine social capital.